Immunoadjuvants enhance the febrile responses of rats to endogenous pyrogen.
The febrile responses of male Sprague-Dawley rats to a semipurified endogenous pyrogen produced from human monocytes were characterized by establishing fever dose-response curves. The animals were then injected intravenously with a number of substances that possessed the common properties of stimulating the phagocytic activity of the cells of the reticuloendothelial system and of acting as immunoadjuvants. The substances used were zymosan, lipopolysaccharide endotoxin, and muramyl dipeptide. Three days after any of these immunoadjuvants were injected, the fever sensitivity of the rats was remeasured. In each case, the slope of the fever dose-response curve tripled, and in some instances the response threshold for fever response was reduced by factors of three to eight. Furthermore, the maximum increase in body temperature produced by the endogenous pyrogen was more than doubled after immunoadjuvant treatment. By contrast latex beads, which are also phagocytized by the cells of the reticuloendothelial system but do not subsequently increase their phagocytic index nor do they enhance immune responses, had no effect on the fever sensitivity of rats in response to endogenous pyrogen. In the light of these findings, it is suggested that the febrile responses of rats to endogenous pyrogen are mediated in some manner by cells that possess some of the properties of reticuloendothelial cells. The location of these putative cells must be close to the circulation, because the immunoadjuvants used in this study were, for the most part, large molecular weight molecules that could not cross the blood-brain barrier easily.
Stitt
J T
JT
John B. Pierce Foundation Laboratory, Yale University School of Medicine, New Haven, Connecticut 06519.
Shimada
S G
SG
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001831:Body Temperature / Q000187:drug effects*; D004357:Drug Synergism; D004731:Endotoxins / Q000494:pharmacology; D006801:Humans; D007840:Latex / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D009000:Monocytes / Q000032:analysis; D012157:Mononuclear Phagocyte System / Q000166:cytology; D010587:Phagocytosis / Q000187:drug effects; D011749:Pyrogens / Q000302:isolation & purification / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains / Q000502:physiology*; D013997:Time Factors; D015054:Zymosan / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D004731:Endotoxins; D007840:Latex; D008070:Lipopolysaccharides; D011749:Pyrogens; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C044101:endotoxin, Escherichia coli; D015054:Zymosan